Metformin Safety Warnings and Diabetes Drug Prescribing Patterns forOlder Nursing Home Residents

摘要

ObjectiveDiabetes mellitus is common in U.S. nursing homes (NH), and the mainstay treatment, metformin, has U.S. Food and Drug Administration (FDA) boxed warnings indicating safety concerns in those with advanced age, heart failure, or renal disease. Little is known about treatment selection in this setting, especially for metformin. We quantified the determinants of initiating sulfonylureas over metformin with the aim of understanding the impact of FDA-labeled boxed warnings in older NH residents.